(Total Views: 718)
Posted On: 03/10/2022 7:00:38 PM
Post# of 72444
Future progress in the broader Brilacidin antiviral program will largely be tied to obtaining government funding for additional clinical development while benefiting from ongoing collaborative research with NIH and other scientists. Brilacidin’s broad-spectrum antiviral activity is generating positive data. Publications and conference abstracts related to this research are being prepared.
Funding is being sought just have to wait and see.
Other NIH benefits-
Preliminary Brilacidin formulation work for inhaled delivery has been conducted, with the NIH APP a potential avenue to expand on this work, along with exploring the subcutaneous administration of Brilacidin, which has greater than 70 percent bioavailability via this route of administration.
Work is being completed behind the scenes. Hopefully we get good news on these endeavors.
Funding is being sought just have to wait and see.
Other NIH benefits-
Preliminary Brilacidin formulation work for inhaled delivery has been conducted, with the NIH APP a potential avenue to expand on this work, along with exploring the subcutaneous administration of Brilacidin, which has greater than 70 percent bioavailability via this route of administration.
Work is being completed behind the scenes. Hopefully we get good news on these endeavors.
(8)
(1)
